Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | NAMPT | P43490 | 5/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3228223 | 0.98 | USP2 (0.44) | USP2NAMPTSIGMAR1TSHRROCK2 | |
| SCHEMBL3227861 | 0.97 | USP2 (0.43) | USP2NAMPTSIGMAR1TSHRROCK2 | |
| SCHEMBL1496985 | 0.95 | USP2 (0.45) | USP2NAMPTSIGMAR1TSHRROCK2 | |
| SCHEMBL3230881 | 0.95 | KDM1A (0.44) | USP2NAMPTTSHRROCK2CD274 | |
| SCHEMBL1496867 | 0.93 | USP2 (0.43) | USP2NAMPTSIGMAR1TSHRROCK2 | |
| SCHEMBL3225988 | 0.93 | USP2 (0.47) | USP2NAMPTTSHRROCK2CD274 | |
| SCHEMBL3223286 | 0.93 | SIGMAR1 (0.45) | USP2NAMPTSIGMAR1 | |
| SCHEMBL8004861 | 0.92 | USP2 (0.45) | USP2NAMPTSIGMAR1TSHRROCK2 | |
| SCHEMBL3230832 | 0.91 | HSD17B10 (0.46) | USP2TSHRHSD17B10POLBKDM4E | |
| SCHEMBL8001525 | 0.91 | POLB (0.42) | USP2NAMPTSIGMAR1TSHRROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012972-B2 | Pyridinecarboxylic acid (2-aminophenyl) amide derivative having urea structure | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-8012972-B2 | Pyridinecarboxylic acid (2-aminophenyl) amide derivative having urea structure | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20100063045-A1 | NOVEL PYRIDINECARBOXYLIC ACID (2-AMINOPHENYL) AMIDE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063045-A1 | NOVEL PYRIDINECARBOXYLIC ACID (2-AMINOPHENYL) AMIDE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2135620-A1 | OCULAR HYPOTENSIVE AGENT COMPRISING COMPOUND CAPABLE OF INHIBITING HISTONE DEACETYLASE AS ACTIVE INGREDIENT | Santen Pharmaceutical Co., Ltd (JP) | 2009-12-23 | — | — | EP | disclosed |
| EP-2133339-A1 | NOVEL (2-AMINOPHENYL)PYRIDINECARBOXAMIDE DERIVATIVE HAVING UREA STRUCTURE | Santen Pharmaceutical Co., Ltd (JP) | 2009-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063045-A1 | NOVEL PYRIDINECARBOXYLIC ACID (2-AMINOPHENYL) AMIDE DERIVATIVE HAVING UREA STRUCTURE | HCAR1, CBR1, UACA | USP2 1702/4885NAMPT 3581/4885SIGMAR1 112/4885 |
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | HDAC1, HDAC9, HDAC5 | USP2 3063/4885NAMPT 719/4885SIGMAR1 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.